Advertisement


Edward B. Garon, MD, on Non–Small Cell Lung Cancer: CheckMate 384 Trial on Nivolumab Dosing

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Edward B. Garon, MD, of the Olive View–UCLA Medical Center, discusses phase IIIb/IV study findings on reducing the frequency of nivolumab dosing, from 480 mg every 4 weeks to 240 mg every 2 weeks, in patients with previously treated advanced non–small cell lung cancer (Abstract 100).



Related Videos

Immunotherapy

Kim A. Margolin, MD, on Promising Immunotherapy Strategies

Kim A. Margolin, MD, of City of Hope, summarizes a session she co-chaired on combination immunotherapies, locoregional therapies, systemic therapies, and enhancing natural killer cells.

Immunotherapy

Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture

Jedd D. Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the data to date on checkpoint blockades and the rationale for combination therapies and novel agents.

Breast Cancer
Immunotherapy

G. Travis Clifton, MD, on Breast Cancer and Disease Recurrence: Final Analysis From a Study of Nelipepimut-S, GM-CSF, and Trastuzumab

G. Travis Clifton, MD, of Brooke Army Medical Center, discusses phase IIb trial findings on nelipepimut-S plus GM-CSF with trastuzumab vs trastuzumab alone to prevent recurrences of high-risk, HER2 low-expressing breast cancer (Abstract 1).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Ziad Bakouny, MD, on Renal Cell Carcinoma: Next-Generation Immuno-oncology Therapies

Toni K. Choueiri, MD, and Ziad Bakouny, MD, both of Dana-Farber Cancer Institute, talk about novel cytokines, checkpoint inhibitors, and vaccines in the treatment pipeline for renal cell carcinoma.

Breast Cancer
Immunotherapy

Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Building on Recent Successes

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute, discusses the encouraging data on atezolizumab plus nab-paclitaxel in the first-line setting for metastatic triple-negative breast cancer, and the potential benefits of combining immune checkpoint inhibitors with targeted treatment in breast cancer.

Advertisement

Advertisement



Advertisement